MIRTAZAPINE 30 MG - Результаты поиска

Австралия - английский - Department of Health (Therapeutic Goods Administration)

apo-mirtazapine mirtazapine 30 mg tablet bottle

arrotex pharmaceuticals pty ltd - mirtazapine, quantity: 30 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 8000; croscarmellose sodium; iron oxide red; microcrystalline cellulose; iron oxide yellow; hyprolose - treatment of major depression including relapse prevention

Австралия - английский - Department of Health (Therapeutic Goods Administration)

apo-mirtazapine mirtazapine 45 mg tablet bottle

arrotex pharmaceuticals pty ltd - mirtazapine, quantity: 45 mg - tablet, film coated - excipient ingredients: hypromellose; macrogol 8000; magnesium stearate; hyprolose; lactose monohydrate; croscarmellose sodium; microcrystalline cellulose; titanium dioxide - treatment of major depression including relapse prevention

Австралия - английский - Department of Health (Therapeutic Goods Administration)

apo-mirtazapine mirtazapine 15 mg tablet bottle

arrotex pharmaceuticals pty ltd - mirtazapine, quantity: 15 mg - tablet, film coated - excipient ingredients: hypromellose; hyprolose; croscarmellose sodium; titanium dioxide; lactose monohydrate; macrogol 8000; iron oxide yellow; microcrystalline cellulose; magnesium stearate - treatment of major depression including relapse prevention

Соединенные Штаты - английский - NLM (National Library of Medicine)

mirtazapine- mirtazapine tablet, film coated

mckesson corporation - mirtazapine (unii: a051q2099q) (mirtazapine - unii:a051q2099q) - mirtazapine 15 mg - mirtazapine tablets are indicated for the treatment of major depressive disorder. the efficacy of mirtazapine tablets in the treatment of major depressive disorder was established in 6 week controlled trials of outpatients whose diagnoses corresponded most closely to the diagnostic and statistical manual of mental disorders – 3rd edition (dsm-iii) category of major depressive disorder (see clinical pharmacology ). a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. the effectiveness of mirtazapine tablets in hospitali